Skip to Content

Table of Contents - The Medical Letter 2013

 Select a year:     [Show summaries][Hide summaries]     SUBSCRIBE     2013 Annual Index: U.S. English | Canadian English

January 7, 2013 (Issue 1407)  
  • Tofacitinib (Xeljanz) for Rheumatoid Arthritis p. 1
    The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to...
  • Probiotics Revisited p. 3
    Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) marketed as dietary supplements. They have not been approved by the FDA for any indication....

January 21, 2013 (Issue 1408)  

February 4, 2013 (Issue 1409)  

February 18, 2013 (Issue 1410)  

March 4, 2013 (Issue 1411)  
  • Drugs for Hypertriglyceridemia p. 17
    Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations...
  • Misoprostol for Miscarriage p. 19
    Misoprostol (Cytotec, and generics), a prostaglandin E1 analog FDA-approved for prevention of NSAID-induced gastric ulcers and, when taken with...
  • Enzalutamide (Xtandi) for Prostate Cancer (online only) p. 20
    The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer...

March 18, 2013 (Issue 1412)  

April 1, 2013 (Issue 1413)  
  • Two New Drugs for Homozygous Familial Hypercholesterolemia p. 25
    The FDA has approved mipomersen (Kynamro – Genzyme) and lomitapide (Juxtapid – Aegerion), each in addition to a low-fat diet and other lipid-lowering...
  • Raxibacumab for Anthrax p. 27
    The FDA has approved raxibacumab (rax” ee bak’ ue mab; GSK), a fully human monoclonal antibody given by intravenous infusion, for treatment of inhalational anthrax in...
  • In Brief: FDA Azithromycin Warning p. 28
    The FDA has announced that it is requiring changes in the labeling of the macrolide antibiotic azithromycin (Zithromax, Zmax) to warn about the risk of QT prolongation...

April 15, 2013 (Issue 1414)  
  • In Brief: Cancer Risk with Salmon Calcitonin p. 29
    Two FDA advisory committees recently concluded that use of a nasal spray formulation of the peptide hormone salmon calcitonin for treatment of postmenopausal osteoporosis is...
  • Teduglutide Injection (Gattex) for Short Bowel Syndrome p. 29
    The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel...
  • Botox for Overactive Bladder p. 31
    The FDA has recently approved intradetrusor injection of onabotulinumtoxinA (Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate...

April 29, 2013 (Issue 1415)  

May 13, 2013 (Issue 1416)  

May 27, 2013 (Issue 1417)  

June 10, 2013 (Issue 1418)  

June 24, 2013 (Issue 1419)  

July 8, 2013 (Issue 1420)  

July 22, 2013 (Issue 1421)  

August 5, 2013 (Issue 1422)  

August 19, 2013 (Issue 1423)  

September 2, 2013 (Issue 1424)  

September 16, 2013 (Issue 1425)  

September 30, 2013 (Issue 1426)  
  • Rethinking Warfarin for Atrial Fibrillation p. 77
    Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis...
  • Dolutegravir (Tivicay) for HIV p. 77
    The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1...
  • Radium-223 (Xofigo) for Prostate Cancer p. 79
    Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer...

October 14, 2013 (Issue 1427)  

October 28, 2013 (Issue 1428)  

November 11, 2013 (Issue 1429)  

November 25, 2013 (Issue 1430)  

December 9, 2013 (Issue 1431)  

December 23, 2013 (Issue 1432)